Subscribe

Enter your email address below to receive our latest content via email.

Connect With Us

This feature has not been activated yet. Install and activate the WordPress Popular Posts plugin.

Site Search.

Pharmaceutical Tariff Elimination Agreement Wto

By on December 14, 2020 in Uncategorized

Box 4.23. European Commission survey on the pharmaceutical sector and related enforcement measures The pharmaceutical agreement is one of the many sectoral initiatives adopted during the Uruguay Round. A number of parties to the General Agreement on Tariffs and Trade (GATT) have agreed to remove and/or reduce tariffs on certain sectors (TN/MA/S/13). Unlike multilateral agreements, these sectoral agreements, as they are called, were signed by and for the groups of participants and not for all WTO members. Participants pledged to implement the results on the basis of the most favoured nation. In addition to their impact on prices, tariffs also affect the conditions of local production initiatives with respect to the cost of inputs such as chemical ingredients, the competitiveness and importance of exports from local producers, and the protection of imported products through tariffs. The downward trend in tariffs on specific and general chemical inputs in the pharmaceutical industry (groups A3 and B1) could help to increase the competitiveness of the local pharmaceutical industry. The tariff data cited above do not provide a conclusive understanding of the effectiveness of efforts to develop local production capacity, but it is clear that tariffs are becoming less important in all of these policy efforts. Box 4.21 briefly describes the sectoral negotiations on public health tariffs at the GATT and the WTO. It is significant that restrictions on the export of pharmaceuticals and necessary medical products have been imposed by industrialized countries such as the United States and some European Union countries, said the Trade Representative.

The latest update, which came into effect on January 1, 2011, added 735 new products to the list of drugs eligible for duty-free treatment. The initial agreement and subsequent updates include more than 10,000 products. 10.21 In 2016, the United Kingdom exported $24.9 billion in pharmaceuticals, of which $11.9 billion (48%) was exported. At the same time, the United Kingdom imported $24.8 billion in medicines and $22 billion in medicines. of which $18.2 billion (73%) a trade deficit of $6.3 billion.24 The Association of the British Pharmaceutical Industry (ABPI) told us that this reflects “45 million packages of medicines, 25 According to the latest report of the WTO secretariat25, the average MFN tax on medical products (including COVID-19 linked to COVID-19) is about 4.8%, or less than 7.6% of the tax on all industrial products. No country is completely independent of the products and devices it needs for its public health systems, which depend most on imports. Trade statistics therefore provide valuable insight into the evolution of models of access to health-related products.

About the Author

About the Author: .

Don't Miss the Next Great Post

If you enjoyed this blog post, subscribe below, and you'll receive an automatic email update when we publish new content.

Comments are closed.

Top